SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

RLAY

Relay Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed12d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the ASH presentation on Dec 14 for updated vascular anomalies data and the regulatory update that follows; also watch for the Phase 3 1L breast cancer trial design confirmation by year-end 2026 and initiation in early 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

RLAY drug pipeline →

zovegalisib

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
The Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.
Next catalyst
None dated

What to watchThe ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$17.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
+6.35%
T+5 · $18.08 · next T+20 in 17d
Vs SPY
+3.06%
α at T+5
Latest observation
+2.24%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $17.00entry
  2. T+1 · 11d ago +9.41%α +9.10% · $18.60
  3. T+5 · 5d ago +6.35%α +3.06% · $18.08
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the $0.43 loss per share in Q3 2025 but wider than the consensus estimate of a $0.40 loss. Revenue was $0, below the $1.6M consensus. The company highlighted faster-than-expected enrollment in the Phase 3 ReDiscover-2 trial for 2L breast cancer (completion now estimated mid-2027), upcoming ASH data for zovegalisib in vascular anomalies, and a cash position of $848.6M sufficient into 2029.

Key Financial Metrics

EPS
−$0.37
est −$0.40 · +7.5%
Revenue
$0.00
est $1.6M · -100.0%
Rating
in line

Key Facts

  • Net loss of $81.7M ($0.37 per share) vs $74.1M ($0.43 per share) in Q3 2025; consensus was $-0.40 EPS
  • Revenue of $0 vs consensus $1.6M; no license revenue in the quarter
  • Cash, cash equivalents and investments of $848.6M as of Sep 30, 2026, down from $910.9M at Jun 30, 2026; runway into 2029
  • Phase 3 ReDiscover-2 trial in 2L breast cancer estimated to complete enrollment in mid-2027, about one year faster than recent benchmarks
  • Updated ReInspire data for zovegalisib in vascular anomalies to be presented at ASH on Dec 14, 2026; regulatory update to follow
  • Shannon Campbell appointed Head of Commercial; previously CCO at Merus and senior roles at Novartis
  • New mutant-selective TIE2 inhibitor program announced, in late-stage preclinical development
  • FDA approved LYRFIGTU (lirafugratinib) for FGFR2 fusion cholangiocarcinoma; licensed to Elevar Therapeutics

Financial Impact

Net loss of $81.7M in Q3 2026, cash burn of ~$62.3M from Q2 to Q3 2026; cash runway into 2029

net losscash positionR&D expenses

Risk Factors

  • No revenue in Q3; pre-commercial stage with no approved products (lirafugratinib licensed out)
  • Cash burn rate of ~$62M/quarter; $848.6M provides runway into 2029 but requires continued trial execution
  • Phase 3 ReDiscover-2 enrollment completion mid-2027 leaves no near-term catalyst from that trial
  • Competitive landscape for PI3Kα inhibitors in breast cancer and vascular anomalies

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395819

Track record

21 reports on RLAY

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +65.12% at T+60 after the May 19, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G Neutral 4/10 Entry $17.68 Now $17.27 −2.29% settles Feb 12
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $17.00 Now $17.27 +1.59% settles Feb 3
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $17.44 Now $17.27 −0.97% settles Feb 1
  6. Oct 7, 20265w ago 144 Neutral 2/10 Entry $17.41 Now $17.27 −0.80% settles Jan 5
  7. Oct 6, 20265w ago 144 Neutral 3/10 Entry $17.95 Now $17.27 −3.79% settles Jan 4
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $18.89 Now $17.27 −8.58% settles Dec 4
  9. Aug 28, 202611w ago Insider Cluster Bearish 6/10 Entry $18.77 Now $17.27 +7.99% settles Nov 23
  10. Aug 18, 202612w ago Insider Cluster Bearish 5/10 Entry $20.74 to $19.72 Now $17.27 +16.73% ▲ +4.92% +4.09% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (9h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026